Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06563024
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-08-18
Brief Title:
18F-FET PETCT in the Management of Glioma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Prospective Investigation in the Utility of Multiparametric 18F-FET PETCT in the Management of Glioma Application of PET Radiomics
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
O-2-18F-fluoroethyl-L-tyrosine FET is a tracer for positron emission tomography PET The Response Assessment in Neuro-Oncology RANO working group has officially recommended 18F-FET PET in the management of patients with brain glioma Recently the utility of 18F-FET PET in the diagnosis of fresh and residual gliomas has been reported by several investigators But clinical usefulness of radiomics parameters has not been explored thoroughly in glioma patients 18F-FET PET has been widely used in clinical studies or routine service in Europe America Mainland China or Japan However 18F-FET PET is still not available in Taiwan In this context the investigator propose this study to explore the role of multiparametric 18F-FET PET imaging for glioma in Taiwan with the emphasis in radiomics analysis
Detailed Description:
Study background
O-2-18F-fluoroethyl-L-tyrosine FET is a tracer for positron emission tomography PET The Response Assessment in Neuro-Oncology RANO working group has officially recommended 18F-FET PET in the management of patients with brain glioma Recently the utility of 18F-FET PET in the diagnosis of fresh and residual gliomas has been reported by several investigators But clinical usefulness of radiomics parameters has not been explored thoroughly in glioma patients 18F-FET PET has been widely used in clinical studies or routine service in Europe America Mainland China or Japan However 18F-FET PET is still not available in Taiwan In this context the investigator propose this study to explore the role of multiparametric 18F-FET PET imaging for glioma in Taiwan
Materials and methods
1 During the pre-treatment work-up the study participants undergo an 18F-FET PETCT scan In addition other routine examinations including MRI with and without contrast enhancement are performed
2 After a definitive diagnosis of primaryrecurrent glioma is confirmed subjects begin treatment surgery radiation therapy chemotherapy etc Within 3 to 6 months after completing treatment the study subjects undergo a second 18F-FET PETCT scan for response evaluation along with a follow-up MRI
O-2-18F-fluoroethyl-L-tyrosine FET is a tracer for positron emission tomography PET The Response Assessment in Neuro-Oncology RANO working group has officially recommended 18F-FET PET in the management of patients with brain glioma Recently the utility of 18F-FET PET in the diagnosis of fresh and residual gliomas has been reported by several investigators But clinical usefulness of radiomics parameters has not been explored thoroughly in glioma patients 18F-FET PET has been widely used in clinical studies or routine service in Europe America Mainland China or Japan However 18F-FET PET is still not available in Taiwan In this context the investigator propose this study to explore the role of multiparametric 18F-FET PET imaging for glioma in Taiwan
Materials and methods
1 During the pre-treatment work-up the study participants undergo an 18F-FET PETCT scan In addition other routine examinations including MRI with and without contrast enhancement are performed
2 After a definitive diagnosis of primaryrecurrent glioma is confirmed subjects begin treatment surgery radiation therapy chemotherapy etc Within 3 to 6 months after completing treatment the study subjects undergo a second 18F-FET PETCT scan for response evaluation along with a follow-up MRI
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None